PEComa with ASPSCR1::TFE3 fusion: expanding the molecular genetic spectrum of TFE3-rearranged PEComa with an emphasis on overlap with alveolar soft part sarcoma

被引:5
|
作者
Zhao, Ming [1 ]
Huang, Yan [2 ]
Yin, Xiaona [1 ]
Xu, Jiayun [1 ]
Sun, Yuefang [3 ]
Wang, Jian [4 ,5 ,6 ]
机构
[1] Ningbo Clin Pathol Diag Ctr, Ningbo, Peoples R China
[2] First Peoples Hosp Linping Dist, Dept Neurol, Hangzhou, Peoples R China
[3] Tongji Univ, Shanghai Peoples Hosp 10, Dept Pathol, Peoples Hosp 10, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Dept Oncol, Inst Pathol, Shanghai, Peoples R China
[6] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200072, Peoples R China
关键词
alveolar soft part sarcoma; ASPSCR1; fusion; perivascular epithelioid cell tumours (PEComa); TFE3; RENAL-CELL CARCINOMA; ASPSCR1-TFE3; FUSION; TUMORS PECOMAS; TFE3; NEOPLASMS; DEFINES; SUBSET;
D O I
10.1111/his.15087
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Mesenchymal neoplasms involving TFE3 gene fusions are diverse, mainly include alveolar soft part sarcoma (ASPS) that is characterised by ASPSCR1::TFE3 fusion, and a small subset of perivascular epithelioid cell tumours (PEComas) referred to as TFE3-rearranged PEComa, that most frequently harbours SFPQ::TFE3 fusion. Historically, ASPS and TFE3-rearranged PEComa are considered two distinctive entities despite their known morphological overlap. However, recent studies have suggested a potential histogenetic relationship between them, and several neoplasms that showed morphological features more closely fit PEComa rather than ASPS but harboured ASPSCR1::TFE3 fusion have been documented. In this study, we report three cases of PEComa with ASPSCR1::TFE3 fusion.Methods and results: Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients are two females and one male with age at presentation ranging from 21 to 51 years. All three tumours were located in the viscera (rectum, kidney and cervix). On a relatively limited follow-up period (range = 9-15 months), all patients are alive without evidence of recurrent or metastatic disease. The neoplasms were composed of tight nested architecture of epithelioid clear cells separated by a delicate vascular network, two of which were associated with sheets of plump spindle cells, and none showed significant discohesive tumour morphology. Immunohistochemically, in addition to TFE3 protein, all three neoplasms demonstrated co-expression of melan-A and smooth muscle actin. RNA-sequencing identified ASPSCR1::TFE3 fusion in all three cases that were confirmed by subsequent fluorescence in-situ hybridisation analyses.Conclusions: Our study expands the molecular genetic spectrum of TFE3-rearranged PEComa and further indicates its close relationship to ASPS.
引用
收藏
页码:482 / 491
页数:10
相关论文
共 50 条
  • [1] TFE3-rearranged pecoma: expanding gene fusion knowledge
    Larque Daza, A. B.
    Frigola, G.
    Castrejon, N.
    Romagosa, C.
    Balaguer, F.
    Castells, A.
    Cuatrecasas, M.
    VIRCHOWS ARCHIV, 2020, 477 : S210 - S211
  • [2] YAP1::TFE3 fusion in a case of malignant TFE3-rearranged PEComa of the lung: expanding the spectrum of pulmonary PEComa-like mesenchymal neoplasms
    Hsu, Ying-Han R.
    Selvarajah, Shamini
    Pal, Prodipto
    Waddell, Thomas K.
    VIRCHOWS ARCHIV, 2025, 486 (03) : 621 - 626
  • [3] ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma
    Miwa Tanaka
    Surachada Chuaychob
    Mizuki Homme
    Yukari Yamazaki
    Ruyin Lyu
    Kyoko Yamashita
    Keisuke Ae
    Seiichi Matsumoto
    Kohei Kumegawa
    Reo Maruyama
    Wei Qu
    Yohei Miyagi
    Ryuji Yokokawa
    Takuro Nakamura
    Nature Communications, 14
  • [4] ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma
    Tanaka, Miwa
    Chuaychob, Surachada
    Homme, Mizuki
    Yamazaki, Yukari
    Lyu, Ruyin
    Yamashita, Kyoko
    Ae, Keisuke
    Matsumoto, Seiichi
    Kumegawa, Kohei
    Maruyama, Reo
    Qu, Wei
    Miyagi, Yohei
    Yokokawa, Ryuji
    Nakamura, Takuro
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [5] ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs
    Sicinska, Ewa
    Kola, Vijaya S. R.
    Kerfoot, Joseph A.
    Taddei, Madeleine L.
    Al-Ibraheemi, Alyaa
    Hsieh, Yi-Hsuan
    Church, Alanna J.
    Landesman-Bollag, Esther
    Landesman, Yosef
    Hemming, Matthew L.
    CANCER RESEARCH, 2024, 84 (14) : 2247 - 2264
  • [6] ASPSCR1-TFE3 fusion in a case of Xp11 translocation PEComa of the liver: are ASPSCR1-TFE3 fusion-bearing tumours Xp11 translocation PEComa or alveolar soft part sarcoma?
    Chai, Jia
    Ma, Jing
    Liu, Yixiong
    Zhao, Danhui
    Yin, Zhiyong
    Wang, Zhe
    Fan, Linn
    PATHOLOGY, 2023, 55 (03) : 416 - 419
  • [7] TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape
    Agaimy, Abbas
    Acosta, Andres M.
    Cheng, Liang
    Collins, Katrina
    Fridman, Eddie
    Schubart, Christoph
    Williamson, Sean R.
    Hartmann, Arndt
    Trpkov, Kiril
    HISTOPATHOLOGY, 2024, 85 (05) : 783 - 793
  • [8] Extrarenal TFE3-Rearranged PEComa: A Clinicopathologic and Molecular Genetic Study of 18 Cases
    Zhu, Peipei
    Weng, I.
    Lao, Annie
    Yu, Lin
    Bai, Qianming
    Zhou, Xiaoyan
    Wang, Jian
    LABORATORY INVESTIGATION, 2024, 104 (03) : S96 - S98
  • [9] Primary intraneural PEComa with ASPSCR1-TFE3 fusion
    Larque Daza, A. B.
    Rojo, L.
    Rodrigo, M.
    Sisuashvili, L.
    Silva, T.
    Hernandez, J.
    Romagosa, C.
    VIRCHOWS ARCHIV, 2024, 485 : S371 - S372
  • [10] TFE3-rearranged Head and Neck Neoplasms: 17 Cases Illustrating Morphological Overlap Between Alveolar Soft Part Sarcoma And PEComa And Highlighting Genotypic Diversity
    Agaimy, Abbas
    Michal, Michael
    Laco, Jan
    Kuroda, Naoto
    Ihrler, Stephan
    Satir, Ali Abdel
    Din, Nasir Ud
    Stoehr, Robert
    Michal, Michal
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1014 - S1015